The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma
In the past decade, the armamentarium of targeted therapy agents for the treatment of metastatic renal cell carcinoma (RCC) has significantly increased. Improvements in response rates and survival, with more manageable side effects compared with interleukin 2/interferon immunotherapy, have been repo...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2016-04-01
|
| Series: | Therapeutic Advances in Urology |
| Online Access: | https://doi.org/10.1177/1756287215612962 |